More to the point, KEVs with controlled size, excellent stability, surface modification of aptamer and active loading of small interfering RNAs thus could fully release the therapeutic potential of siSTAT3 in PC9-GR4-AZD1 NSCLC subcutaneous xenografts in mice, which could be emerged as a better clinical choice for NSCLC patients after EGFR-TKIs resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.